BUY Aurobindo Pharma — Siddharth Rai Mangala, 25 Aug 2026

bySiddharth Rai MangalaHorizon: NA (inferred Intraday)25 Aug 2026, 2:23 pm ISTvia Zee Business (Live)

Entry₹1,621.6Inferred

Target₹1,648

Stop loss₹1,605-1.02% risk

At expiry₹1,614.925 Aug 2026, 3:05 pm

Expired-0.41%

Follow Siddharth Rai Mangala for new calls(15% target hit, 62 closed calls)Get alerts Watch AUROPHARMA for new buy/sell callsGet alerts See 1 active Intraday call on AUROPHARMA See 17 active Intraday picks this session

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

Frozen at close · 25 Aug 2026

2 supporting1 neutral1 opposing

Supports the BUY call (2)

Aurobindo Pharma Share Price Gains As USFDA Concludes Inspection At Subsidiary Lannett's Unit

NewsNdtv-Profit·24 Aug · yesterday

Aurobindo Pharma US FDA inspection ends with one observation at AuroPeptides facility

NewsCnbc-Tv18·21 Aug · 3d ago

Neutral / worth noting (1)

Here's why these four pharma stocks are in focus today

NewsCnbc-Tv18·24 Aug · yesterday

Weighs against the BUY call (1)

Aurobindo Pharma US subsidiary Lannett Company LLC faces 4 observations from the USFDA

NewsLivemint·24 Aug · yesterday

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.